These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 11602791)

  • 1. Immunity against both polyomavirus VP1 and a transgene product induced following intranasal delivery of VP1 pseudocapsid-DNA complexes.
    Clark B; Caparrós-Wanderley W; Musselwhite G; Kotecha M; Griffin BE
    J Gen Virol; 2001 Nov; 82(Pt 11):2791-2797. PubMed ID: 11602791
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Molecular cloning and expression of major structural protein VP1 of the human polyomavirus JC virus: formation of virus-like particles useful for immunological and therapeutic studies.
    Goldmann C; Petry H; Frye S; Ast O; Ebitsch S; Jentsch KD; Kaup FJ; Weber F; Trebst C; Nisslein T; Hunsmann G; Weber T; Lüke W
    J Virol; 1999 May; 73(5):4465-9. PubMed ID: 10196348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hamster polyomavirus-derived virus-like particles are able to transfer in vitro encapsidated plasmid DNA to mammalian cells.
    Voronkova T; Kazaks A; Ose V; Ozel M; Scherneck S; Pumpens P; Ulrich R
    Virus Genes; 2007 Jun; 34(3):303-14. PubMed ID: 16927120
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protective efficacy of rotavirus 2/6-virus-like particles combined with CT-E29H, a detoxified cholera toxin adjuvant.
    Siadat-Pajouh M; Cai L
    Viral Immunol; 2001; 14(1):31-47. PubMed ID: 11270595
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the C-terminal region of vervet monkey polyomavirus 1 VP1 in virion formation.
    Yamaguchi H; Kobayashi S; Maruyama J; Sasaki M; Takada A; Kimura T; Sawa H; Orba Y
    J Vet Med Sci; 2014 May; 76(5):637-44. PubMed ID: 24419975
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Murine pneumotropic virus VP1 virus-like particles (VLPs) bind to several cell types independent of sialic acid residues and do not serologically cross react with murine polyomavirus VP1 VLPs.
    Tegerstedt K; Andreasson K; Vlastos A; Hedlund KO; Dalianis T; Ramqvist T
    J Gen Virol; 2003 Dec; 84(Pt 12):3443-3452. PubMed ID: 14645925
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Persistence and tissue distribution of DNA in normal and immunodeficient mice inoculated with polyomavirus VP1 pseudocapsid complexes or polyomavirus.
    Heidari S; Krauzewicz N; Kalantari M; Vlastos A; Griffin BE; Dalianis T
    J Virol; 2000 Dec; 74(24):11963-5. PubMed ID: 11090197
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Protective immunity against heterologous challenge with encephalomyocarditis virus by VP1 DNA vaccination: effect of coinjection with a granulocyte-macrophage colony stimulating factor gene.
    Sin JI; Sung JH; Suh YS; Lee AH; Chung JH; Sung YC
    Vaccine; 1997 Dec; 15(17-18):1827-33. PubMed ID: 9413089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Modification to the capsid of the adenovirus vector that enhances dendritic cell infection and transgene-specific cellular immune responses.
    Worgall S; Busch A; Rivara M; Bonnyay D; Leopold PL; Merritt R; Hackett NR; Rovelink PW; Bruder JT; Wickham TJ; Kovesdi I; Crystal RG
    J Virol; 2004 Mar; 78(5):2572-80. PubMed ID: 14963160
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Murine polyomavirus virus-like particles (VLPs) as vectors for gene and immune therapy and vaccines against viral infections and cancer.
    Tegerstedt K; Franzén AV; Andreasson K; Joneberg J; Heidari S; Ramqvist T; Dalianis T
    Anticancer Res; 2005; 25(4):2601-8. PubMed ID: 16080500
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cellular and humoral immune responses to chimeric EGFP-pseudocapsids derived from the mouse polyomavirus after their intranasal administration.
    Fric J; Marek M; Hrusková V; Holán V; Forstová J
    Vaccine; 2008 Jun; 26(26):3242-51. PubMed ID: 18468739
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Segments of puumala hantavirus nucleocapsid protein inserted into chimeric polyomavirus-derived virus-like particles induce a strong immune response in mice.
    Gedvilaite A; Zvirbliene A; Staniulis J; Sasnauskas K; Krüger DH; Ulrich R
    Viral Immunol; 2004; 17(1):51-68. PubMed ID: 15018662
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric bacteriophage fr virus-like particles harboring the immunodominant C-terminal region of hamster polyomavirus VP1 induce a strong VP1-specific antibody response in rabbits and mice.
    Voronkova T; Grosch A; Kazaks A; Ose V; Skrastina D; Sasnauskas K; Jandrig B; Arnold W; Scherneck S; Pumpens P; Ulrich R
    Viral Immunol; 2002; 15(4):627-43. PubMed ID: 12513932
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of adaptive immune responses against antigens incorporated within the capsid of simian virus 40.
    Saika K; Kato M; Sanada H; Matsushita S; Matsui M; Handa H; Kawano M
    J Gen Virol; 2020 Aug; 101(8):853-862. PubMed ID: 32501197
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Packaging of small molecules into VP1-virus-like particles of the human polyomavirus JC virus.
    Goldmann C; Stolte N; Nisslein T; Hunsmann G; Lüke W; Petry H
    J Virol Methods; 2000 Oct; 90(1):85-90. PubMed ID: 11011084
    [TBL] [Abstract][Full Text] [Related]  

  • 16. VP1, the major capsid protein of the mouse polyomavirus, binds microtubules, promotes their acetylation and blocks the host cell cycle.
    Horníková L; Fraiberk M; Man P; Janovec V; Forstová J
    FEBS J; 2017 Jan; 284(2):301-323. PubMed ID: 27885808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Development of a vaccine marker technology: display of B cell epitopes on the surface of recombinant polyomavirus-like pentamers and capsoids induces peptide-specific antibodies in piglets after vaccination.
    Neugebauer M; Walders B; Brinkman M; Ruehland C; Schumacher T; Bertling WM; Geuther E; Reiser CO; Reichel C; Strich S; Hess J
    Biotechnol J; 2006 Dec; 1(12):1435-46. PubMed ID: 17109492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevailing Sydney like Norovirus GII.4 VLPs induce systemic and mucosal immune responses in mice.
    Huo Y; Wan X; Ling T; Wu J; Wang Z; Meng S; Shen S
    Mol Immunol; 2015 Dec; 68(2 Pt A):367-72. PubMed ID: 26375574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BPV1 E2 protein enhances packaging of full-length plasmid DNA in BPV1 pseudovirions.
    Zhao KN; Hengst K; Liu WJ; Liu YH; Liu XS; McMillan NA; Frazer IH
    Virology; 2000 Jul; 272(2):382-93. PubMed ID: 10873782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic immunization is augmented by murine polyomavirus VP1 pseudocapsids.
    Rollman E; Ramqvist T; Zuber B; Tegerstedt K; Kjerrström Zuber A; Klingström J; Eriksson L; Ljungberg K; Hinkula J; Wahren B; Dalianis T
    Vaccine; 2003 Jun; 21(19-20):2263-7. PubMed ID: 12744856
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.